UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)   April 22, 2020

 

REPRO MED SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

 

New York

0-12305

13-3044880

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)


24 Carpenter Road, Chester, New York

10918

(Address of principal executive offices)

(Zip Code)


Registrant’s telephone number, including area code   (845) 469-2042

 

not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  [_]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

common stock, $0.01 par value

KRMD

NASDAQ Capital Market

 



ITEM 5.07  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS


Set forth below are the voting results from the 2020 Annual Meeting of Shareholders held on April 22, 2020:


PROPOSAL 1:  ELECTION OF DIRECTORS


The nominees for director set forth under “Nominees” below were elected to the Company’s board of directors.


 

NUMBER OF SHARES

NOMINEES

FOR

WITHHELD

BROKER NON-VOTE

Daniel S. Goldberger

24,467,135

30,729

8,840,134

R. John Fletcher

24,406,493

91,371

8,840,134

David W. Anderson

24,455,353

42,511

8,840,134

Joseph M. Manko, Jr.

24,369,007

128,857

8,840,134

Robert T. Allen

24,444,360

53,504

8,840,134

James M. Beck

24,453,860

44,004

8,840,134

Kathy S. Frommer

24,456,880

40,984

8,840,134


PROPOSAL 2:  ADVISORY VOTE - EXECUTIVE COMPENSATION


The Company’s shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers.


 

FOR

AGAINST

ABSTAIN

BROKER NON-VOTE

Number of Shares

23,879,212

79,870

538,782

8,840,134


PROPOSAL 3:  RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS


The Company’s shareholders ratified the appointment of McGrail Merkel Quinn & Associates, P.C. as the Company’s independent registered public accountants for the 2020 fiscal year.


 

FOR

AGAINST

ABSTAIN

Number of Shares

33,299,121

22,670

16,207



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 

REPRO MED SYSTEMS, INC.
(Registrant)

 

 

 

Date:  April 24, 2020

By:

/s/ Karen Fisher

 

Karen Fisher
Chief Financial Officer


- 2 -


Repro Med Systems (NASDAQ:REPR)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Repro Med Systems Charts.
Repro Med Systems (NASDAQ:REPR)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Repro Med Systems Charts.